<i>HspA1B</i>Is a Prognostic Biomarker and Correlated With Immune Infiltrates in different subtypes of Breast Cancers

He, Jie; Wang, H

doi:10.1101/725861

Cited by 7 publications

(3 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The HSPA1B protein is a member of the heat shock protein 70 family that encodes a 70 kDa heat shock protein, also known as heat shock protein 70-2 (HSP70-2). HSP70 is a stress-inducible molecular chaperone with key roles that involve polypeptide refolding and degradation [ 40 ]. In our study, the HSPA1B expression was found to be decreased in cancer compared to erythroplakia.…”

Section: Resultsmentioning

confidence: 99%

Label-Free Proteomics of Oral Mucosa Tissue to Identify Potential Biomarkers That Can Flag Predilection of Precancerous Lesions to Oral Cell Carcinoma: A Preliminary Study

et al. 2023

View full text Add to dashboard Cite

Oral squamous cell carcinomas are mostly preceded by precancerous lesions such as leukoplakia and erythroplakia. Our study is aimed at identifying potential biomarker proteins in precancerous lesions of leukoplakia and erythroplakia that can flag their transformation to oral cancer. Four biological replicate samples from clinical phenotypes of healthy control, leukoplakia, erythroplakia, and oral carcinoma were annotated based on clinical screening and histopathological evaluation of buccal mucosa tissue. Differentially expressed proteins were delineated using a label-free quantitative proteomic experiment done on an Orbitrap Fusion Tribrid mass spectrometer in three technical replicate sets of samples. Raw files were processed using MaxQuant version 2.0.1.0, and downstream analysis was done via Perseus version 1.6.15.0. Validation included functional annotation based on biological processes and pathways using the ClueGO plug-in of Cytoscape. Hierarchical clustering and principal component analysis were performed using the ClustVis tool. Across control, leukoplakia, and cancer, L-lactate dehydrogenase A chain, plectin, and WD repeat-containing protein 1 were upregulated, whereas thioredoxin 1 and spectrin alpha chain, nonerythrocytic 1 were downregulated. Across control, erythroplakia, and cancer, L-lactate dehydrogenase A chain was upregulated whereas aldehyde dehydrogenase 2, peroxiredoxin 1, heat shock 70 kDa protein 1B, and spectrin alpha chain, nonerythrocytic 1 were downregulated. We found that proteins involved in leukoplakia were associated with alteration in cytoskeletal disruption and glycolysis, while in erythroplakia, they were associated with alteration in response to oxidative stress and glycolysis across phenotypes. Hierarchical clustering subgrouped half of precancerous samples under the main branch of the control and the remaining half under carcinoma. Similarly, principal component analysis identified segregated clusters of control, precancerous lesions, and cancer, but erythroplakia phenotypes, in particular, overlapped more with the cancer cluster. Qualitative and quantitative protein signatures across control, precancer, and cancer phenotypes explain possible functional outcomes that dictate malignant transformation to oral carcinoma.

show abstract

Section: Resultsmentioning

confidence: 99%

Label-Free Proteomics of Oral Mucosa Tissue to Identify Potential Biomarkers That Can Flag Predilection of Precancerous Lesions to Oral Cell Carcinoma: A Preliminary Study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The gene expression level of the LPAR6 in various types of cancers was determined via Oncomine, 19 as we previously described. 20 The threshold was set as follows: p-value of 1E-6, fold-change of 2, and gene ranking top 5%.…”

Section: Gene Expression Level Determination Of Lpar6mentioning

confidence: 99%

A Novel Prognostic Biomarker LPAR6 in Hepatocellular Carcinoma via Associating with Immune Infiltrates

He¹,

Meng²,

Wang³

2021

J Clin Transl Hepatol

Self Cite

View full text Add to dashboard Cite

Background and Aims: LPAR6 is the most recently determined G protein-coupled receptor of lysophosphatidic acid, and hardly any study has demonstrated the performance of LPAR6 in cancers. We sought to clarify the relationship of LPAR6 to prognosis potential and tumor infiltration immune cells in different cancers. Methods: The expression of LPAR6 and its clinical characteristics were evaluated on various databases. The association between LPAR6 and immune infiltrates of various types of cancer were investigated via TIMER. Results: We determined that higher LPAR6 expression level was associated with a better overall survival. Additionally, high LPAR6 expression level was significantly associated with better disease-specific survival (DSS) in bladder cancer, and better overall survival (OS)/ progression-free survival (PFS)/ distant metastasis-free survival (DMFS)/ relapse-free survival (RFS) in breast cancer and some other types of cancers. Moreover, LPAR6 significantly affects the prognosis of various cancers via The Cancer Genome Atlas (TCGA). Further research exposed that the mRNA level of LPAR6 was positively coordinated with infiltrating levels of devious immune cells in hepatocellular carcinoma. Conclusions: Our results imply that LPAR6 is associated with prognosis potential and immune infiltration levels in liver cancer. Moreover, LPAR6 expression possibly contributes to the activation of CD8+ T, naive T, effector T cells and natural killer cells and inactivates T regulatory cells, decreases T cell exhaustion and regulate T helper cells in liver cancer. These discoveries imply that LPAR6 could be a novel biomarker of prognosis for indicating prognosis potential and immune-infiltrating level in hepatocellular carcinoma.

show abstract

“…ACE2 is the key enzyme in the renin‐angiotensin system (RAS), both of which are involved in pathological vessel growth and beneficial angiogenesis and it is also related to tumorigenesis 12,13 . Moreover, many researchers have demonstrated that the tumor‐infiltrating lymphocytes (TILs) play an important part in intervening the chemotherapy response and enhancing clinical prognosis especially survival rates of different cancer types, 14,15 such as tumor‐associated macrophages (TAMs) 16–18 and tumor‐infiltrating neutrophils (TINs), and they also impact the outcomes of cancers 19–22 . Therefore, it is also essential to clarify the immunophenotyping of tumor immunocyte interactions and description of novel immunotherapy targets/strategy in cancer therapy.…”

Section: Introductionmentioning

confidence: 99%

Construction of a risk map to understand the vulnerability of various types of cancer patients to COVID‐19 infection

Yang

Wang

2021

MedComm

Self Cite

View full text Add to dashboard Cite

COVID‐19 is leading to a global pandemic and invades human cells via ACE2. ACE2 was found to be abundantly expressed in many organs and cells. However, there is no evidence about the potential risk of various types of cancer patients vulnerable to the infection of COVID‐19. To obtain a risk map that indicates the novel coronavirus vulnerability of different types of cancer, we analyzed in this work the RNA sequencing datasets of cancer patients. By interrogating the datasets, we not only identified the cancer types vulnerable to COVID‐19 attacks, but also we reported that variations in the mRNA expression level of ACE2 correlate to various prognosis phenomenon in different types of cancer cohorts, and illustrated the underlying mechanism involved or may be related to lymphocytes infiltration. From these discoveries, we constructed an infection risk map, which indicates the vulnerability of different types of cancer to COVID‐19 infection, also elucidated the correlationship between ACE2 and the prognosis of cancer. We found that high ACE2 expression levels lead to high risk of COVID‐19 infection and poor prognosis of breast invasive carcinoma (BRCA), while better prognosis in ovarian serous cystadenocarcinoma (OV) patient cohorts. Moreover, our study demonstrated that this different pattern may correlate with the immune infiltration level.

show abstract

HspA1BIs a Prognostic Biomarker and Correlated With Immune Infiltrates in different subtypes of Breast Cancers

Cited by 7 publications

References 60 publications

Label-Free Proteomics of Oral Mucosa Tissue to Identify Potential Biomarkers That Can Flag Predilection of Precancerous Lesions to Oral Cell Carcinoma: A Preliminary Study

Label-Free Proteomics of Oral Mucosa Tissue to Identify Potential Biomarkers That Can Flag Predilection of Precancerous Lesions to Oral Cell Carcinoma: A Preliminary Study

A Novel Prognostic Biomarker LPAR6 in Hepatocellular Carcinoma via Associating with Immune Infiltrates

Construction of a risk map to understand the vulnerability of various types of cancer patients to COVID‐19 infection

Contact Info

Product

Resources

About